CDK1 and ovarian carcinoma: Hyperactivation of CDK1 is associated with poor prognosis for patients with lung adenocarcinoma (Shi et al., 2016), ovarian cancer (Yang et al., 2016), renal cell carcinoma(Hongo et al., 2014), and breast cancer (Pavlou et al., 2014).